These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11366792)

  • 21. AACTG recommendations for metabolic problems. Guide covers insulin resistance and diabetes.
    AIDS Alert; 2003 Jan; 18(1):6. PubMed ID: 12541993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control.
    Blass SC; Ellinger S; Vogel M; Ingiliz P; Spengler U; Stehle P; von Ruecker A; Rockstroh JK
    Eur J Med Res; 2008 May; 13(5):209-14. PubMed ID: 18559303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperproinsulinaemia in normoglycaemic lipodystrophic HIV-infected patients.
    Haugaard SB; Andersen O; Hales CN; Halsall I; Rosenfalck AM; Iversen J; Madsbad S
    Eur J Clin Invest; 2006 Jun; 36(6):436-45. PubMed ID: 16684128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
    De Socio GV; Bonfanti P; Ricci E; Orofino G; Madeddu G; Penco G; Gianelli E; Martinelli C; Carradori S; Quirino T; Rizzardini G;
    Biomed Pharmacother; 2008 Jan; 62(1):16-20. PubMed ID: 17851026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children.
    Bitnun A; Sochett E; Dick PT; To T; Jefferies C; Babyn P; Forbes J; Read S; King SM
    J Clin Endocrinol Metab; 2005 Jan; 90(1):168-74. PubMed ID: 15483082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV protease inhibitors and dyslipidemia.
    Clotet B; Negredo E
    AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.
    Calmy A; Petoumenos K; Lewden C; Law M; Bocquentin F; Hesse K; Cooper D; Carr A; Bonnet F;
    HIV Med; 2007 Apr; 8(3):171-80. PubMed ID: 17461861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weighty matters.
    Beesley S; Maurice J
    STEP Perspect; 1998; 98(3):13-5. PubMed ID: 11365824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
    Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
    Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lipid profile for treatment with protease inhibitors].
    Livrozet JM
    Med Mal Infect; 2006 Jul; 36 Suppl 2():S212-7. PubMed ID: 17075999
    [No Abstract]   [Full Text] [Related]  

  • 36. Protease inhibitors and body shape changes.
    TreatmentUpdate; 1998 Apr; 10(2):4-5. PubMed ID: 11365437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health advisory: high blood sugar and diabetes seen in protease inhibitor users.
    Crit Path AIDS Proj; 1998; (No 33):31-2. PubMed ID: 11366367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protease inhibitors' metabolic side effects: cholesterol, triglycerides, blood sugar, and "Crix belly." Interview with Lisa Capaldini, M.D. Interview by John S. James.
    Capaldini L
    AIDS Treat News; 1997 Aug; (No 277):1-4. PubMed ID: 11364559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protease paunch?
    Munk B
    Posit Aware; 1997; 8(6):20-1. PubMed ID: 11364856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease inhibitors, diabetes mellitus and blood lipids.
    Meyer L; Rabaud C; Ziegler O; May T; Drouin P
    Diabetes Metab; 1998 Dec; 24(6):547-9. PubMed ID: 9932223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.